Clinical Trial Detail

NCT ID NCT02159066
Title LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications

melanoma

Therapies

Binimetinib + Encorafenib + Ribociclib

Binimetinib + Encorafenib

Binimetinib + Capmatinib + Encorafenib

Binimetinib + Buparlisib + Encorafenib

Binimetinib + Encorafenib + Infigratinib

Age Groups: adult

Additional content available in CKB BOOST